Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics r&d expenses
Research and development expenses are spending on new products and technology.
Myriad Genetics's R&D Expenses for the twelve months ending Jun 30, 2026 was $105.80M, down 7.0% year over year. For fiscal 2025 it was $106.80M, down 5.8% from the year before. Over ten years it grew 4.7% a year on average. The highest annual figure on record is $113.40M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.80M | -5.8% |
| FY2024 | Dec 31, 2024 | $113.40M | +27.8% |
| FY2023 | Dec 31, 2023 | $88.70M | +3.9% |
| FY2022 | Dec 31, 2022 | $85.40M | +10.6% |
| FY2020 | Jun 30, 2020 | $77.20M | -10.1% |
| FY2019 | Jun 30, 2019 | $85.90M | +21.3% |
| FY2018 | Jun 30, 2018 | $70.80M | -4.8% |
| FY2017 | Jun 30, 2017 | $74.40M | +5.4% |
| FY2016 | Jun 30, 2016 | $70.60M | -6.5% |
| FY2015 | Jun 30, 2015 | $75.50M | +11.9% |
| FY2014 | Jun 30, 2014 | $67.50M | +25.7% |
| FY2013 | Jun 30, 2013 | $53.70M | +25.9% |
| FY2012 | Jun 30, 2012 | $42.65M | +53.7% |
| FY2011 | Jun 30, 2011 | $27.75M | +26.9% |
| FY2010 | Jun 30, 2010 | $21.87M | +22.1% |
| FY2009 | Jun 30, 2009 | $17.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $25.00M | -2.3% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $27.10M | -1.5% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $25.50M | -20.8% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $28.20M | -1.1% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $25.60M | -5.5% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $27.50M | +10.4% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $32.20M | +53.3% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $28.50M | +18.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $27.10M | +27.8% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $24.90M | +10.7% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $21.00M | -10.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $24.00M | +17.1% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $21.20M | +4.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $22.50M | +6.1% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $23.40M | +34.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $20.50M | +4.1% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $20.30M | +8.0% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $21.20M | -0.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $17.40M | -16.7% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $19.70M | -8.4% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $18.80M | -16.1% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $21.30M | +0.9% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $20.90M | +18.1% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $21.50M | +16.2% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $22.40M | +33.3% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $21.10M | +18.5% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $17.70M | -5.9% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $18.50M | +5.1% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $16.80M | -9.7% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $17.80M | -8.2% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $18.80M | -3.6% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $17.60M | +2.3% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $18.60M | +11.4% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $19.40M | +12.8% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $19.50M | +4.3% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $17.20M | +3.0% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $16.70M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $17.20M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $18.70M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $16.70M | – |
See a number that looks wrong?